Journal of clinical gastroenterology
-
J. Clin. Gastroenterol. · Aug 2004
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialParecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects.
The gastrointestinal safety of the novel injectable cyclooxygenase-2 selective inhibitor, parecoxib sodium, was compared with the nonselective nonsteroidal anti-inflammatory drug, ketorolac, and placebo in healthy subjects. ⋯ Parecoxib sodium 40 mg twice daily for 7 days has a gastrointestinal safety profile superior to ketorolac 30 mg 4 times daily for 5 days, and comparable to placebo.
-
J. Clin. Gastroenterol. · Aug 2004
Case ReportsPrimary endoscopic management of esophageal perforation following transesophageal echocardiogram.
A 90-year-old woman sustained a proximal esophageal perforation following transesophageal echocardiography. The perforation originated at the site of a Zenker's diverticulum and resulted in a false passage to the diaphragm. ⋯ Following stabilization, the patient had repair of her Zenker's diverticulum and recovered uneventfully. We recommend that all procedures involving blind intubation of the esophagus should be preceded with specific pursuit of a background of cervical dysphagia.